A multi-center, double-blind, randomized, placebo-controlled trial protocol to assess Traumeel injection vs dexamethasone injection in rotator cuff syndrome: the TRAumeel in ROtator cuff syndrome (TRARO) study protocol

Abstract

BackgroundShoulder pain is a common musculoskeletal symptom with a wide range of potential causes; however, the majority of conditions can be managed with conservative treatment. The aim of this study is to assess the efficacy and safety of Traumeel injections versus corticosteroid injections and placebo in the treatment of rotator cuff syndrome and bursitis and expand the current evidence base for the conservative treatment of rotator cuff syndrome.Methods/DesignThis is a multi-center, randomized, double-blind, 16-week, three-arm, parallel-group, active- and placebo-controlled trial to assess the efficacy and safety of Traumeel 2 ml injection versus dexamethasone 8 mg injection versus placebo (saline solution). Patients will be randomly allocated to Traumeel, dexamethasone or placebo in a 2:2:1 randomization. After 1 week screening, patients will receive 3 injections at weekly intervals (days 1, 8 and 15) with additional follow-up assessments on day 22, a telephone consultation in week 9 and a final visit at week 15. Male and female patients aged 40 to 65 years, inclusive, will be recruited if they have acute episodes of chronic rotator cuff syndrome and/or bursitis. Patients with calcifications in the shoulder joint or a complete rotator cuff tear will be excluded. At least 160 patients will be recruited. All subacromial injections will be performed under ultrasound guidance utilizing a common technique. The only rescue medication permitted will be paracetamol (acetaminophen), with usage recorded. The primary endpoint is change from baseline in abduction-rotation pain visual analog scale (0–100 mm scale, 0 corresponds to no pain and 100 to extreme pain) at day 22 (Traumeel injections versus dexamethasone injections) for active external rotation. Secondary efficacy parameters include range of motion, disability of arm, shoulder, hand score and patient’s/investigator’s global assessment. Clinical efficacy will be assessed as non-inferiority of Traumeel with respect to dexamethasone regarding the primary efficacy parameter.DiscussionIt is hoped that the results of this trial will expand the treatment options and evidence base available for the management of rotator cuff disease.Trial registrationClinicalTrials.gov: NCT01702233. EudraCT number: 2012-003393-12.

Calf Blood Compound (CFC) and Homeopathic Drug Induce Differentiation of Primary Human Skeletal Muscle Cells

“…A previous study with the C2C12 cell line demonstrated an improvement of cell proliferation after treatment with different concentrations of Calf Blood Copmpound (CFC) [15]. Tr14 is a homeopathic solution with a fixed combination formula of 12 botanical and two mineral substances with demonstrated anti-inflammatory, anti-edematous as well as anti-exudative properties [17]. In vitro studies revealed that Tr14 inhibits the production of pro-inflammatory cytokines like TNF-α and IL-1β [18].…”

Critical Literature Review of the Homeopathic Compound Traumeel for Treatment of Inflammation

“…Deleterious side effects of NSAIDs include heart attack, stroke, peptic ulcers, gastrointestinal bleeding, and kidney disease. Current limitations of these medications and their side effect profiles warrant an effective, safer and better-tolerated medication [13].…”

Intramuscular Injection of Combined Calf Blood Compound (CFC) and Homeopathic Drug Tr14 Accelerates Muscle Regeneration In Vivo

“…Tr14 is a homeopathic solution that possesses anti-edematous, anti-exudative, and anti-inflammatory properties [17]. Tr14 consists of a combination of two minerals and twelve botanical substances.…”